Evaluation of the Effectiveness of Continuous Glucose Monitors on Glycemic Control in Patients With Type 2 Diabetes Receiving Institutional Financial Assistance
Main finding · HbA1c, CGM cohort, before vs after CGMResult — go to the resultMean difference −0.6 %Authors' conclusion
Overall, there is a statistical and clinical improvement in HbA1c before and after implementation of CGMs in patients with type 2 diabetes who meet Medicaid criteria for CGM coverage receiving financial assistance.
Study context
- Population
- Adults with T2D receiving institutional financial assistance for continuous glucose monitoring (CGMs); CGM cohort mostly Hispanic (77%) and uninsured (77%)
- Exposure
- Hemoglobin A1c (HbA1c) before vs after CGM implementation; cohort with no CGM use for comparison
- Outcome
- Change in HbA1c from baseline after CGM implementation
- Follow-up
- Approximately three months
Methodological detailssingle-centre
- Single-centre
Main finding
HbA1c, CGM cohort, before vs after CGM · three months post-CGM
Mean difference
−0.6 %
P = 0.004
As reported in the abstract
- Average HbA1c prior to CGM
- 8.3%
- Average HbA1c three months post-CGM
- 7.7%
Observational data: associations, not effects.
Secondary outcomes
Antidiabetic agents, total daily insulin dose, ED visits, hospitalizations (pre vs post CGM)
- No statistically significant differences pre vs post CGM
Original publication
Evaluation of the Effectiveness of Continuous Glucose Monitors on Glycemic Control in Patients With Type 2 Diabetes Receiving Institutional Financial Assistance. J Diabetes Sci Technol. Published 20 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →